You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Author Index Volume 28 (2016)

The issue number is given in front of the page numbers

Abi-Jaoude, E., see Le Noury, J. (3) 143–161

Afifi, S., see Peymani, P. (1) 25–31

Alvarez, P.A., D.T. Nguyen, R. Schutt, C. Ganduglia, J.D. Estep, E.A. Graviss and D. Putney, In-hospital use of non-steroidal anti-inflammatory drugs in patients with heart failure in academic centers in the United States (4) 181–188

Amsterdam, J.D., see Jureidini, J.N. (1) 33–43

Awodele, O., A. Ibrahim and P. Orhii, Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014 (1) 13–23

Baldo, V., see Buja, A. (3) 163–170

Bassi, P., see Ogunleye, O.O. (2) 77–91

Buja, A., A.M. Saieva, A. Vinelli, R.M. Cacco, K. Ottolitri, E. De Battisti, C. Dario and V. Baldo, Adverse event reporting and patient safety at a University Hospital: Mapping, correlating and associating events for a data-based patient risk management (3) 163–170

Cacco, R.M., see Buja, A. (3) 163–170

Cohen, D., see Hughes, S. (2) 101–114

Cruz, R.S., see dos Reis, C. (1) 45–60

Danborg, P.B., see Simonsen, A.L. (1) 1–12

Dario, C., see Buja, A. (3) 163–170

De Battisti, E., see Buja, A. (3) 163–170

Dias, J.J., see Mehta, S. (2) 65–75

dos Reis, C., R. Teixo, F. Mendes and R.S. Cruz, Biosimilar medicines – Review (1) 45–60

Ekoja, M., see Ogunleye, O.O. (2) 77–91

El-Enein, N.Y.A., see Zaghloul, A.A. (2) 93–99

Enwere, O., see Ogunleye, O.O. (2) 77–91

Estep, J.D., see Alvarez, P.A. (4) 181–188

Falade, C., see Ogunleye, O.O. (2) 77–91

Ganduglia, C., see Alvarez, P.A. (4) 181–188

Gøtzsche, P.C., see Simonsen, A.L. (1) 1–12

Graviss, E.A., see Alvarez, P.A. (4) 181–188

Grech, V., Response to a Letter to the Editor (3) 175 –176

Healy, D., J. Le Noury and D. Mangin, Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence (3) 125–141

Healy, D., see Le Noury, J. (3) 143–161

Heydari, S.T., see Peymani, P. (1) 25–31

Hughes, S., D. Cohen and R. Johnson, Adverse event assessment methods in published trials of psychotropic drugs: Poor reporting and neglect of emerging safety concerns (2) 101–114

Ibrahim, A., see Awodele, O. (1) 13–23

Isah, A., see Ogunleye, O.O. (2) 77–91

Jargin, S.V., Concerning a Letter to the Editor (3) 171–174

Johnson, R., see Hughes, S. (2) 101–114

Jørgensen, K.J., see Ziganshina, L.E. (4) 221–226

Jureidini, J., see Le Noury, J. (3) 143–161

Jureidini, J.N., J.D. Amsterdam and L.B. McHenry, The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance (1) 33–43

Kapp, M.B., Defensive medicine: No wonder policymakers are confused (4) 213–219

Kapp, M.B., Front office staff as medical educators, risk creators, and risk managers (1) 61–64

Kilani, J., see Ogunleye, O.O. (2) 77–91

Kolfschoten, J., see Rolfes, L. (2) 115–123

Kooijman, M., see Rolfes, L. (2) 115–123

Kwon, C.S., E. Seoane-Vazquez and R. Rodriguez-Monguio, FDA safety actions for antidiabetic drugs marketed in the US, 1980–2015 (4) 197–211

Lankarani, K.B., see Peymani, P. (1) 25–31

Le Noury, J., J.M. Nardo, D. Healy, J. Jureidini, M. Raven, C. Tufanaru and E. Abi-Jaoude, Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression (3) 143–161

Le Noury, J., see Healy, D. (3) 125–141

Maharlouei, N., see Peymani, P. (1) 25–31

Mangin, D., see Healy, D. (3) 125–141

McHenry, L.B., see Jureidini, J.N. (1) 33–43

Mehta, S., H.P. Singh and J.J. Dias, Effect of patient safety incident review and reflection in an extended morbidity and mortality meeting (2) 65–75

Mendes, F., see dos Reis, C. (1) 45–60

Namazi, S., see Peymani, P. (1) 25–31

Nardo, J.M., see Le Noury, J. (3) 143–161

Nguyen, D.T., see Alvarez, P.A. (4) 181–188

Nouraei, H., see Peymani, P. (1) 25–31

Obiako, R., see Ogunleye, O.O. (2) 77–91

Obodo, J., see Ogunleye, O.O. (2) 77–91

Odesanya, R., see Ogunleye, O.O. (2) 77–91

Ogundele, S.O., see Ogunleye, O.O. (2) 77–91

Ogunleye, O.O., I.A. Oreagba, C. Falade, A. Isah, O. Enwere, S. Olayemi, S.O. Ogundele, R. Obiako, R. Odesanya, P. Bassi, J. Obodo, J. Kilani and M. Ekoja, Medication errors among health professionals in Nigeria: A national survey (2) 77–91

Olayemi, S., see Ogunleye, O.O. (2) 77–91

Oreagba, I.A., see Ogunleye, O.O. (2) 77–91

Orhii, P., see Awodele, O. (1) 13–23

Ottolitri, K., see Buja, A. (3) 163–170

Peymani, P., R. Tabrizi, S. Afifi, S. Namazi, S.T. Heydari, M.K. Shirazi, H. Nouraei, E. Sadeghi, K.B. Lankarani and N. Maharlouei, Knowledge, attitude and practice of General Practitioners towards adverse drug reaction reporting in South of Iran, Shiraz (Pharmacoepidemiology report) (1) 25–31

Putney, D., see Alvarez, P.A. (4) 181–188

Rahman, S.A., see Zaghloul, A.A. (2) 93–99

Raven, M., see Le Noury, J. (3) 143–161

Rodriguez-Monguio, R., see Kwon, C.S. (4) 197–211

Rolfes, L., J. Kolfschoten, F. van Hunsel, M. Kooijman and E. van Puijenbroek, Actions in response to drug safety signals arising from a spontaneous reporting system: Retrospective study in The Netherlands (2) 115–123

Sadeghi, E., see Peymani, P. (1) 25–31

Saieva, A.M., see Buja, A. (3) 163–170

Scherb, H., Comment on a Letter to the Editor (3) 177 –180

Schutt, R., see Alvarez, P.A. (4) 181–188

Seoane-Vazquez, E., see Kwon, C.S. (4) 197–211

Shirazi, M.K., see Peymani, P. (1) 25–31

Simonsen, A.L., P.B. Danborg and P.C. Gøtzsche, Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies (1) 1–12

Singh, H.P., see Mehta, S. (2) 65–75

Tabrizi, R., see Peymani, P. (1) 25–31

Teixo, R., see dos Reis, C. (1) 45–60

Tufanaru, C., see Le Noury, J. (3) 143–161

van Hunsel, F., see Rolfes, L. (2) 115–123

van Puijenbroek, E., see Rolfes, L. (2) 115–123

Vinelli, A., see Buja, A. (3) 163–170

Yaxley, J., Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence (4) 189–196

Zaghloul, A.A., S.A. Rahman and N.Y.A. El-Enein, Obligation towards medical errors disclosure at a tertiary care hospital in Dubai, UAE (2) 93–99

Ziganshina, L.E. and K.J. Jørgensen, The first ever Cochrane event in Russia and Russian speaking countries – Cochrane Russia Launch – Evidence-based medicine: Achievements and barriers (QiQUM 2015) International Conference, Kazan, December 7-8, 2015 (4) 221–226